Big pharma's future: panel discussion
This article was originally published in Scrip
Executive Summary
Big pharma companies are expected to turn a corner in 2016, when the decline in prescription drug revenues should stem, with a return to annual growth then forecast. This is the finding of a new report, The Outlook for Big Pharma, published by Datamonitor Healthcare, in which revenues from a group of 16 top big pharma companies are forecast to grow from $439bn in 2014 to $499bn in 2024.